Keyphrases
Inflammatory Bowel Disease
100%
Vedolizumab
100%
Response Predictors
100%
Ustekinumab
100%
Best Location
40%
Therapeutic Target
20%
Severe Disease
20%
Interleukin-12 (IL-12)
20%
Activity Biomarkers
20%
Crohn's Colitis
20%
Crohn's Disease
20%
Biological Agents
20%
Armamentarium
20%
Anti-tumor Necrosis Factor Therapy
20%
Anti-tumor Necrosis Factor (anti-TNF)
20%
Immunogenicity
20%
Integrin
20%
Prior Surgery
20%
New Treatment Options
20%
PubMed Search
20%
Inflammatory Biomarkers
20%
Clinical Activity
20%
Comprehensive Literature Review
20%
IBD Patients
20%
Biological Therapy
20%
Long-term Maintenance
20%
Anti-tumor Necrosis Factor-α Agents
20%
IBD Therapy
20%
Medicine and Dentistry
Inflammatory Bowel Disease
100%
Vedolizumab
100%
Ustekinumab
100%
Tumor Necrosis Factor
42%
Disease
28%
Crohn's Disease
28%
Interleukin 12
14%
Ulcerative Colitis
14%
Biological Marker
14%
Biological Product
14%
Integrin
14%
Patient History of Surgery
14%
Biological Therapy
14%
Immunogenicity
14%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Vedolizumab
100%
Ustekinumab
100%
Tumor Necrosis Factor
42%
Disease
28%
Crohn's Disease
28%
Biological Marker
14%
Interleukin 12
14%
Biological Product
14%
Ulcerative Colitis
14%
Integrin
14%
Immunogenicity
14%
Patient History of Surgery
14%
Immunology and Microbiology
Inflammatory Bowel Disease
100%
Vedolizumab
100%
Ustekinumab
100%
Tumor Necrosis Factor Alpha
42%
Crohn's Disease
28%
Medline
14%
Biological Product
14%
Immunogenicity
14%
Integrin
14%
Ulcerative Colitis
14%
Interleukin 12
14%